Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition

5 Mar

Written By Aleks

Paternot S, Raspé E, Meiller C, Tarabichi M, Assié JB, Libert F, Remmelink M, Bisteau X, Pauwels P, Blum Y, Le Stang N, Tabone-Eglinger S, Galateau-Salle F, Blanquart C, Van Meerbeeck JP, Berghmans T, Jean D, Roger PP. bioRxiv (april 2022) doi: https://doi.org/10.1101/2022.04.11.487857

Aleks

Monoclonal antibodies to activated CDK4: Use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition

Monoclonal antibodies to activated CDK4: Use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27

The Atypical Chemerin Receptor GPR1 Displays Different Modes of Interaction with β-arrestins in Humans and Mice with Important Consequences on Subcellular Localization and Trafficking